First, NDR1 expression levels and its downstream effectors like FBXO11 and β-catenin could serve as prognostic markers for prostate cancer progression and metastasis since patients with lower NDR1 expression or dysregulated activity in this pathway may have a higher risk of aggressive disease and poor outcomes. Here, FBXO11 is linked to prostate carcinoma.